To confirm whether EZH2 inhibitors, especially EPZ6438, have a superior role in managing cervical cancers, especially HPV-associated cervical cancers, further studies incorporating a larger cell-sample size, perhaps even including patient-derived samples, are necessary. Here, EZH2 is linked to cervical carcinoma.